健择联合顺铂治疗晚期非小细胞肺癌疗效观察

Effect of Combined Chemotherapy of Gemcitabine and Cisplatin in the Treatment of Advanced Non-Small Cell Lung Cancer

目的 :探讨健择 (gemcitabine ,gemzar,GEM)联合顺铂治疗晚期非小细胞肺癌 (NSCLC)的疗效。方法 :36例初治晚期NSCLC患者应用健择 1g m2 ,静脉滴入 ,d1、d8,顺铂 10 0mg m2 ,静脉滴入 ,d1,每 2 1d为 1个周期 ,2～ 3个周期后评价疗效和毒副作用。结果 :完全缓解 (CR) 1例 ,部分缓解 (PR) 14例 ,总缓解率 4 1 7% ,中位生存期 39周 ,1年生存率 4 4 4 %。主要不良反应为骨髓抑制和恶心、呕吐。结论 :健择联合顺铂是治疗晚期NSCLC疗效较好方案 ,毒性可耐受。

Objective To study the efficacy and toxicity of gemcitabine plus cisplatin in the treatment of advanced non small cell lung cancer (NSCLC).Methods Thirty six previously untreated patients with advanced NSCLC received combined chemotherapy of gemcitabine and cisplatin,gemcitabine 1 g/m 2,iv infusion,on days 1 and 8;cisplatin 100 mg/m 2,iv infusion,on day 1,repeated every 21 days.Assessment was given after 2 of 3 cycles.Results CR 1 case,PR 14 cases,the overall response rate was 41.7%,the median survival time was 39 weeks,1 year survival rate was 44.4%.The main side effects were myelosuppression,nausea,vomiting.Conclusions Gemcitabine plus cisplatin is a better regimen for the treatment of advaced NSCLC,the side effects were tolerable.